With US Food and Drug Administration clearance of Bio-Rad Laboratories’ new clinical Droplet Digital PCR instrument and an assay to monitor treatment of chronic myeloid leukemia patients, the company now sees opportunities to rapidly grow the menu available on the clinical diagnostics system. The firm plans to add more oncology tests as well as noninvasive prenatal testing and newborn screening assays through both in-house development and partnerships with thirdparty assay makers.

Source : Genomeweb

>> Read full article